Brief: Inozyme Pharma Inc Company To Share Topline Data From Ongoing Phase 1/2 Trials Of Inz-701 In Enpp1 Deficiency And Abcc6 Deficiency At Virtual Event
09/01/2023 13:57
Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA INC: COMPANY TO SHARE TOPLINE DATA FROM
ONGOING
PHASE 1/2 TRIALS OF INZ-701 IN ENPP1 DEFICIENCY AND ABCC6
DEFICIENCY AT VIRTUAL EVENT
* INOZYME PHARMA INC: SIGNIFICANT CLINICAL AND SCIENTIFIC
MILESTONES ACROSS ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY PROGRAMS
ACHIEVED IN 2022
Source text for Eikon: ID:nGNX7HRPZ2
Further company coverage: INZY.O
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin